MarketResearch.com: iPSC Research Products Continue 14.7% Annual Growth During Human Clinical Trials, According to BioInformant Report
WASHINGTON and NEW YORK and LONDON, Oct. 30, 2014 /PRNewswire/ -- As a leading provider of market research, MarketResearch.com announces the distribution of a report by BioInformant Worldwide, LLC, revealing the continued 14.7% annual growth of the induced pluripotent stem cell (iPSC) market.
To learn more about the induced pluripotent stem cell market, visit: http://www.marketresearch.com/land/product.asp?productid=8077502&progid=86801
Since the discovery of iPSCs in 2006, several market forces have gained momentum, but never before has there been such a rare combination of landmark events supporting the development of iPSC tools and technologies as has occurred during 2014. Taken in aggregate, these events have driven funding awards, supported large initial public offerings, inspired patent challenges, and more. For companies and investors competing within the iPSC market, it is important to understand the implications of these events and how they affect your ability compete within the marketplace.
Recently released, the "Complete 2013-14 Induced Pluripotent Stem Cell Industry Report" provides strategic guidance for companies commercializing induced pluripotent stem cell (iPSC) products and technologies. Three of the most important market forces discussed within the report are explored below.
First Ever Clinical Trial in Humans: iPSCs Implanted into Humans in Japan
Without question, the most momentous milestone has been initiation of the first clinical research trial involving transplant of iPSCs into humans. It was initiated in August 2013 to investigate the safety of iPSC-derived cell sheets for restoring vision in patients with wet age-related macular degeneration. It is now underway at the Riken Center in Japan, led by Dr. Masayo Takahashi, and will continue throughout 2015, with safety and vision restoration monitoring lasting beyond the trial end date.
Previously, all trials underway with iPSCs involved only the creation of iPSC lines from specific patient populations and evaluation of these lines for determining whether they could represent a good model for a disease of interest within that population. Currently, a search of the ClinicalTrials.gov website (a worldwide database for clinical trials) shows there are 26 trials underway for the creation such iPSC lines.
iPSC Funding Gains Momentum: Increases Observed in Grant Funding, Public Stock Offerings, and More
Another key iPSC market force has been the recent increase in funding flowing into the iPSC marketplace. In March of 2013, Celullar Dynamics International (CDI) and the Coriell Institute for Medical Research announced receiving $16 million and $10 dollars grants, respectively, from the California Institute for Regenerative Medicine (CIRM) for the creation of iPSC lines from 3,000 healthy and diseased donors to create the world's largest human iPSC bank.
Furthermore, a large research products market has grown into existence for iPSCs. According to BioInformant Worldwide, LLC, a stem cell research firm, the number of iPSC research products sold worldwide has been growing at an annual rate of 14.7% for the past five years. In addition, 22% of stem cell researchers now report having used iPSCs within a research project. These benchmarks indicate that increasingly large quantities of iPSC research products are now being utilized.
Historic iPSC Patent Dispute (Even Bigger Than WARF?)
A final force impacting the iPSC market is a historic patent dispute that has exploded onto the scene, one that could potentially rival the infamous Wisconsin Alumni Research Foundation (WARF) dispute surrounding patents for derivation of human embryonic stem cells (hESCs).
In 2006, Drs. Yamanaka and Takahashi filed a U.S. patent claiming a method for creating iPSCs titled "Oct3/4, Klf4, c-Myc and Sox2 produce induced pluripotent stem cells," which was issued as U.S. Patent No. 8,058,065 on November 15, 2011. Known as the "Yamanaka Patent," it is the dominant patent relating to cellular reprogramming and creation of iPSCs. However, it is now being challenged in a patent lawsuit by a group called "BioGatekeeper." If successful in canceling the Yamanaka Patent, it could spur incredible innovation within the stem cell space by allowing for lower cost creation of iPSC products, technologies, and therapies.
"Landmark events have rapidly accelerated innovation in the iPSC sector, and competition in the industry has followed," said BioInformant. "To compete in the evolving iPSC marketplace, you need to know key industry benchmarks and be positioned to take action."
Summary of Report Findings
Because the iPSC marketplace is rapidly evolving, the "Complete 2013-14 Induced Pluripotent Stem Cell Industry Report" positions company executives to make informed decisions. Key findings from the report include:
- Charts, Timelines, and Financials for the iPSC Product Market
- Trends for iPSC Grants, Scientific Publications, and Patents
- 5-Year Market Size Projections (2014-2018)
- Competitive Environment Analysis, including Determination of Market Leaders
- Preferred Species for iPSC Research
- iPSC Product Categories (Breakdown of Market Share by Each)
- Consumer Behavioral Patterns and Preferred Providers
- Crucial Trends and Unmet Market Needs
- "Tested Language" for Influencing iPSC Researchers
- Breakdown of the Marketing Methods, including Exposure and Response Rates
- End-User Survey of iPSC Researchers (131 U.S. / 143 International)
To learn more about the induced pluripotent stem cell market, visit: http://www.marketresearch.com/land/product.asp?productid=8077502&progid=86801
About MarketResearch.com
MarketResearch.com is the leading provider of global market intelligence products and services. With research reports from more than 720 top consulting and advisory firms, MarketResearch.com offers instant online access to the world's most extensive database of expert insights on global industries, companies, products, and trends. Moreover, MarketResearch.com's Research Specialists have in-depth knowledge of the publishers and the various types of reports in their respective industries and are ready to provide research assistance.
Follow us on Facebook http://www.facebook.com/marketresearchdotcom
Follow us on Twitter http://www.twitter.com/marketresearch_
About BioInformant Worldwide, LLC
BioInformant Worldwide, LLC, specializes in global strategic reports for the stem cell industry and is the only research firm that has specifically served the stem cell sector since it emerged. BioInformant has been featured on prominent news outlets that include Nature Biotechnology, the Wall Street Journal, CBS News, Yahoo Finance, Medical Ethics, MarketWatch, the Center for BioNetworking, and many more. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, Goldman Sachs, and Beckton Dickinson, BioInformant is your trusted source of stem cell industry data. To access BioInformant reports, please visit www.MarketResearch.com.
MarketResearch.com
240.747.3008
[email protected]
Logo - http://photos.prnewswire.com/prnh/20140801/132627
SOURCE MarketResearch.com
Share this article